Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Mayr, Luzia M ^a   Cohen, Sandra ^a   Spurrier, Brett ^a   Kong, Xiang Peng ^a   Zolla Pazner, Susan ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LEUCINE; MONOCLONAL ANTIBODY; PHENYLALANINE; PROTEIN ANTIBODY; THREONINE; TYROSINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; WILD TYPE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING SITES; CELL LINE; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84880816240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070859     Document Type: Article

References (39)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
3. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E,et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature.
4. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343.
5. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010) Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6: e1001249.
6. Zolla-Pazner S, Cardozo T, (2010) Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 10: 527-535.
7. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, et al. (1994) Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 68: 8312-8320.
8. Israel ZR, Gorny MK, Palmer C, McKeating JA, Zolla-Pazner S, (1997) Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. AIDS 11: 128-130.
9. Shotton C, Arnold C, Sattentau Q, Sodroski J, McKeating JA, (1995) Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 69: 222-230.
10. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
11. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: 301-309.
12. Wagner N, Lohler J, Kunkel EJ, Ley K, Leung E, et al. (1996) Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 382: 366-370.
13. Bargatze RF, Jutila MA, Butcher EC, (1995) Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity 3: 99-108.
14. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, et al. (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: 20877-20882.
15. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, et al. (2011) The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog 7: e1001301.
16. Zeller Y, Mechtersheimer S, Altevogt P, (2001) Critical amino acid residues of the alpha4 subunit for alpha4beta7 integrin function. J Cell Biochem 83: 304-319.
17. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, et al. (2012) Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 8: e1002686.
18. Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, et al. (1994) Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol 68: 400-410.
19. McKeating JA, Shotton C, Jeffs S, Palmer C, Hammond A, et al. (1996) Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. Immunol Lett 51: 101-105.
20. Gorny MK, Pan R, Williams C, Wang XH, Volsky B, et al. (2012) Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 427: 198-207.
21. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
22. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD,et al. (2013) Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity.
23. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. Aids 15: W1-W25.
24. Stamatatos L, Lim M, Cheng-Mayer C, (2000) Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res Hum Retroviruses 16: 981-994.
25. Stamatatos L, Wiskerchen M, Cheng-Mayer C, (1998) Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses 14: 1129-1139.
26. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L, (1997) Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 71: 1657-1661.
27. Zhang JX, Cai MB, Wang XP, Duan LP, Shao Q, et al. (2013) Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol 30: 390.
28. Gorny MK, VanCott TC, Williams C, Revesz K, Zolla-Pazner S, (2000) Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology 267: 220-228.
29. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, et al. (2000) Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol. 74: 7096-7107.
30. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215.
31. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, et al. (1999) Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73: 1974-1979.
32. Raman S, Vernon R, Thompson J, Tyka M, Sadreyev R, et al. (2009) Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins 77Suppl 9: 89-99.
33. Wang C, Bradley P, Baker D, (2007) Protein-protein docking with backbone flexibility. J Mol Biol 373: 503-519.
34. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, et al. (2005) Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79: 5232-5237.
35. Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, et al. (2011) Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J Virol 85: 4578-4585.
36. Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z, (1998) Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16: 1803-1811.
37. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359.
38. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, et al. (2005) Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528-6531.
39. Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, et al. (2013) Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. PLoS One 8: e53629.